SCHEMBL3519132

SCHEMBL3519132

O=C(O)[C@@]1(c2ccc(Cl)c(F)c2)CCCC[C@H]1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 12/20 0.56
SLC6A4 P31645 9/20 0.56
TRPA1 O75762 1/20 0.42
CYP3A4 P08684 2/20 0.41
AKR1C3 P42330 2/20 0.41
AKR1C2 P52895 2/20 0.41
APP P05067 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
SLC6A2 P23975 1/20 0.41
AKR1C1 Q04828 1/20 0.38
CCR1 P32246 1/20 0.36
USP2 O75604 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521373 1.00 SLC6A3 (0.56) SLC6A3SLC6A4TRPA1CYP3A4AKR1C3
SCHEMBL3519139 1.00 SLC6A3 (0.56) SLC6A3SLC6A4TRPA1CYP3A4AKR1C3
SCHEMBL3519135 1.00 SLC6A3 (0.56) SLC6A3SLC6A4TRPA1CYP3A4AKR1C3
SCHEMBL3521370 1.00 SLC6A3 (0.56) SLC6A3SLC6A4TRPA1CYP3A4AKR1C3
SCHEMBL5086938 0.88 SLC6A3 (0.56) SLC6A3SLC6A4CYP3A4CYP2C19SLC6A2
SCHEMBL3516421 0.88 SLC6A3 (0.56) SLC6A3SLC6A4CYP3A4CYP2C19SLC6A2
SCHEMBL3516424 0.88 SLC6A3 (0.56) SLC6A3SLC6A4CYP3A4CYP2C19SLC6A2
SCHEMBL3516420 0.88 SLC6A3 (0.56) SLC6A3SLC6A4CYP3A4CYP2C19SLC6A2
SCHEMBL3521655 0.88 SLC6A3 (0.56) SLC6A3SLC6A4CYP3A4CYP2C19SLC6A2
SCHEMBL3521657 0.88 SLC6A3 (0.56) SLC6A3SLC6A4CYP3A4CYP2C19SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562878-B2 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARAMCEUTICALS INC. (US) 2020-02-18 US disclosed
US-9868718-B2 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2018-01-16 US disclosed
EP-1976513-B1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC (US) 2016-08-24 EP disclosed
US-20150126511-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC. 2015-05-07 US disclosed
US-8877975-B2 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2014-11-04 US disclosed
US-20100190861-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC. 2010-07-29 US disclosed
US-20070203111-A1 Cycloalkylamines as monoamine reuptake inhibitors SEPRACOR INC. (US) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150126511-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 SLC6A3 4/4885SLC6A4 5/4885TRPA1 2319/4885
US-20070203111-A1 Cycloalkylamines as monoamine reuptake inhibitors SLC18A2, SLC6A2, SLC18A3 SLC6A3 4/4885SLC6A4 5/4885TRPA1 2319/4885
US-20100190861-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 SLC6A3 4/4885SLC6A4 5/4885TRPA1 2319/4885
US-10562878-B2 Cycloalkylamines as monoamine reuptake inhibitors SLC18A2, SLC6A2, SLC18A3 SLC6A3 4/4885SLC6A4 5/4885TRPA1 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.